Accurate Classification of Diffuse Large B-Cell Lymphoma into Germinal Center and Activated B-Cell Subtypes Using a Nuclease Protection Assay on Formalin-Fixed, Paraffin-Embedded Tissues

Classification of diffuse large B-cell lymphoma (DLBCL) into cell-of-origin (COO) subtypes based on gene expression profiles has well-established prognostic value. These subtypes, termed germinal center B cell (GCB) and activated B cell (ABC) also have different genetic alterations and overexpressio...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinical cancer research 2011-06, Vol.17 (11), p.3727-3732
Hauptverfasser: RIMSZA, Lisa M, WRIGHT, George, TUBBS, Raymond R, BRAZIEL, Rita M, DELABIE, Jan, MILLER, Tom P, STAUDT, Louis M, SCHWARTZ, Mark, CHAN, Wing C, JAFFE, Elaine S, GASCOYNE, Randy D, CAMPO, Elias, ROSENWALD, Andreas, OTT, German, COOK, James R
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 3732
container_issue 11
container_start_page 3727
container_title Clinical cancer research
container_volume 17
creator RIMSZA, Lisa M
WRIGHT, George
TUBBS, Raymond R
BRAZIEL, Rita M
DELABIE, Jan
MILLER, Tom P
STAUDT, Louis M
SCHWARTZ, Mark
CHAN, Wing C
JAFFE, Elaine S
GASCOYNE, Randy D
CAMPO, Elias
ROSENWALD, Andreas
OTT, German
COOK, James R
description Classification of diffuse large B-cell lymphoma (DLBCL) into cell-of-origin (COO) subtypes based on gene expression profiles has well-established prognostic value. These subtypes, termed germinal center B cell (GCB) and activated B cell (ABC) also have different genetic alterations and overexpression of different pathways that may serve as therapeutic targets. Thus, accurate classification is essential for analysis of clinical trial results and planning new trials by using targeted agents. The current standard for COO classification uses gene expression profiling (GEP) of snap frozen tissues, and a Bayesian predictor algorithm. However, this is generally not feasible. In this study, we investigated whether the qNPA technique could be used for accurate classification of COO by using formalin-fixed, paraffin-embedded (FFPE) tissues. We analyzed expression levels of 14 genes in 121 cases of R-CHOP-treated DLBCL that had previously undergone GEP by using the Affymetrix U133 Plus 2.0 microarray and had matching FFPE blocks. Results were evaluated by using the previously published algorithm with a leave-one-out cross-validation approach. These results were compared with COO classification based on frozen tissue GEP profiles. For each case, a probability statistic was generated indicating the likelihood that the classification by using qNPA was accurate. When data were dichotomized into GCB or non-GCB, overall accuracy was 92%. The qNPA technique accurately categorized DLBCL into GCB and ABC subtypes, as defined by GEP. This approach is quantifiable, applicable to FFPE tissues with no technical failures, and has potential for significant impact on DLBCL research and clinical trial development.
doi_str_mv 10.1158/1078-0432.CCR-10-2573
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3107869</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>907155832</sourcerecordid><originalsourceid>FETCH-LOGICAL-c472t-d8efdbd74a368cf75240d8f1960d3a49981c67bf6e712db87d594a2b219949453</originalsourceid><addsrcrecordid>eNqFUstu1DAUjRCIlsIngLxBbEjxM042SEPoFKQRVNCurRs_WqMkHuykYn6Nr8OhMwVWrHxtn3Pu6xTFc4JPCRH1G4JlXWLO6GnbfikJLqmQ7EFxTISQJaOVeJjjA-aoeJLSN4wJJ5g_Lo4oYRXHTBwXP1dazxEmi9oeUvLOa5h8GFFw6L13bk4WbSBeW_SubG3fo81u2N6EAZAfp4DObRz8CD1q7TjZiGA0aKUnf5sVzYHyde6m3dYmdJX8eI0AfZp1byErX8QwWf073yol2KEcrEMcoPdjufY_rHmNLiCCc_l-NnTWmCx76VOabXpaPHLQJ_tsf54UV-uzy_ZDufl8_rFdbUrNJZ1KU1tnOiM5sKrWTgrKsakdaSpsGPCmqYmuZOcqKwk1XS2NaDjQjpKm4Q0X7KR4e6e7nbvBGp07jdCrbfQDxJ0K4NW_P6O_UdfhVrFl_lWTBV7tBWL4nguf1OCTzpOB0YY5qQbLvLWa0f8ia1nXFFNWZaS4Q-oYUorW3ddDsFoMopbkalm-ygZZXheDZN6Lv5u5Zx0ckQEv9wBIGnoXYdQ-_cFxSqjAkv0CqKPGhw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>878820236</pqid></control><display><type>article</type><title>Accurate Classification of Diffuse Large B-Cell Lymphoma into Germinal Center and Activated B-Cell Subtypes Using a Nuclease Protection Assay on Formalin-Fixed, Paraffin-Embedded Tissues</title><source>AACR Journals</source><source>MEDLINE</source><source>Alma/SFX Local Collection</source><source>EZB Electronic Journals Library</source><creator>RIMSZA, Lisa M ; WRIGHT, George ; TUBBS, Raymond R ; BRAZIEL, Rita M ; DELABIE, Jan ; MILLER, Tom P ; STAUDT, Louis M ; SCHWARTZ, Mark ; CHAN, Wing C ; JAFFE, Elaine S ; GASCOYNE, Randy D ; CAMPO, Elias ; ROSENWALD, Andreas ; OTT, German ; COOK, James R</creator><creatorcontrib>RIMSZA, Lisa M ; WRIGHT, George ; TUBBS, Raymond R ; BRAZIEL, Rita M ; DELABIE, Jan ; MILLER, Tom P ; STAUDT, Louis M ; SCHWARTZ, Mark ; CHAN, Wing C ; JAFFE, Elaine S ; GASCOYNE, Randy D ; CAMPO, Elias ; ROSENWALD, Andreas ; OTT, German ; COOK, James R</creatorcontrib><description>Classification of diffuse large B-cell lymphoma (DLBCL) into cell-of-origin (COO) subtypes based on gene expression profiles has well-established prognostic value. These subtypes, termed germinal center B cell (GCB) and activated B cell (ABC) also have different genetic alterations and overexpression of different pathways that may serve as therapeutic targets. Thus, accurate classification is essential for analysis of clinical trial results and planning new trials by using targeted agents. The current standard for COO classification uses gene expression profiling (GEP) of snap frozen tissues, and a Bayesian predictor algorithm. However, this is generally not feasible. In this study, we investigated whether the qNPA technique could be used for accurate classification of COO by using formalin-fixed, paraffin-embedded (FFPE) tissues. We analyzed expression levels of 14 genes in 121 cases of R-CHOP-treated DLBCL that had previously undergone GEP by using the Affymetrix U133 Plus 2.0 microarray and had matching FFPE blocks. Results were evaluated by using the previously published algorithm with a leave-one-out cross-validation approach. These results were compared with COO classification based on frozen tissue GEP profiles. For each case, a probability statistic was generated indicating the likelihood that the classification by using qNPA was accurate. When data were dichotomized into GCB or non-GCB, overall accuracy was 92%. The qNPA technique accurately categorized DLBCL into GCB and ABC subtypes, as defined by GEP. This approach is quantifiable, applicable to FFPE tissues with no technical failures, and has potential for significant impact on DLBCL research and clinical trial development.</description><identifier>ISSN: 1078-0432</identifier><identifier>ISSN: 1557-3265</identifier><identifier>EISSN: 1557-3265</identifier><identifier>DOI: 10.1158/1078-0432.CCR-10-2573</identifier><identifier>PMID: 21364035</identifier><identifier>CODEN: CCREF4</identifier><language>eng</language><publisher>Philadelphia, PA: American Association for Cancer Research</publisher><subject>Antineoplastic agents ; B-Lymphocyte Subsets - pathology ; Biological and medical sciences ; Gene Expression Profiling ; Gene Expression Regulation, Neoplastic ; Germinal Center - pathology ; Hematologic and hematopoietic diseases ; Humans ; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis ; Lymphocyte Activation - genetics ; Lymphoma, Large B-Cell, Diffuse - genetics ; Lymphoma, Large B-Cell, Diffuse - pathology ; Medical sciences ; Nuclease Protection Assays ; Oligonucleotide Array Sequence Analysis ; Paraffin Embedding ; Pharmacology. Drug treatments ; Prognosis</subject><ispartof>Clinical cancer research, 2011-06, Vol.17 (11), p.3727-3732</ispartof><rights>2015 INIST-CNRS</rights><rights>2011 AACR.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c472t-d8efdbd74a368cf75240d8f1960d3a49981c67bf6e712db87d594a2b219949453</citedby><cites>FETCH-LOGICAL-c472t-d8efdbd74a368cf75240d8f1960d3a49981c67bf6e712db87d594a2b219949453</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,3356,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=24212507$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21364035$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>RIMSZA, Lisa M</creatorcontrib><creatorcontrib>WRIGHT, George</creatorcontrib><creatorcontrib>TUBBS, Raymond R</creatorcontrib><creatorcontrib>BRAZIEL, Rita M</creatorcontrib><creatorcontrib>DELABIE, Jan</creatorcontrib><creatorcontrib>MILLER, Tom P</creatorcontrib><creatorcontrib>STAUDT, Louis M</creatorcontrib><creatorcontrib>SCHWARTZ, Mark</creatorcontrib><creatorcontrib>CHAN, Wing C</creatorcontrib><creatorcontrib>JAFFE, Elaine S</creatorcontrib><creatorcontrib>GASCOYNE, Randy D</creatorcontrib><creatorcontrib>CAMPO, Elias</creatorcontrib><creatorcontrib>ROSENWALD, Andreas</creatorcontrib><creatorcontrib>OTT, German</creatorcontrib><creatorcontrib>COOK, James R</creatorcontrib><title>Accurate Classification of Diffuse Large B-Cell Lymphoma into Germinal Center and Activated B-Cell Subtypes Using a Nuclease Protection Assay on Formalin-Fixed, Paraffin-Embedded Tissues</title><title>Clinical cancer research</title><addtitle>Clin Cancer Res</addtitle><description>Classification of diffuse large B-cell lymphoma (DLBCL) into cell-of-origin (COO) subtypes based on gene expression profiles has well-established prognostic value. These subtypes, termed germinal center B cell (GCB) and activated B cell (ABC) also have different genetic alterations and overexpression of different pathways that may serve as therapeutic targets. Thus, accurate classification is essential for analysis of clinical trial results and planning new trials by using targeted agents. The current standard for COO classification uses gene expression profiling (GEP) of snap frozen tissues, and a Bayesian predictor algorithm. However, this is generally not feasible. In this study, we investigated whether the qNPA technique could be used for accurate classification of COO by using formalin-fixed, paraffin-embedded (FFPE) tissues. We analyzed expression levels of 14 genes in 121 cases of R-CHOP-treated DLBCL that had previously undergone GEP by using the Affymetrix U133 Plus 2.0 microarray and had matching FFPE blocks. Results were evaluated by using the previously published algorithm with a leave-one-out cross-validation approach. These results were compared with COO classification based on frozen tissue GEP profiles. For each case, a probability statistic was generated indicating the likelihood that the classification by using qNPA was accurate. When data were dichotomized into GCB or non-GCB, overall accuracy was 92%. The qNPA technique accurately categorized DLBCL into GCB and ABC subtypes, as defined by GEP. This approach is quantifiable, applicable to FFPE tissues with no technical failures, and has potential for significant impact on DLBCL research and clinical trial development.</description><subject>Antineoplastic agents</subject><subject>B-Lymphocyte Subsets - pathology</subject><subject>Biological and medical sciences</subject><subject>Gene Expression Profiling</subject><subject>Gene Expression Regulation, Neoplastic</subject><subject>Germinal Center - pathology</subject><subject>Hematologic and hematopoietic diseases</subject><subject>Humans</subject><subject>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</subject><subject>Lymphocyte Activation - genetics</subject><subject>Lymphoma, Large B-Cell, Diffuse - genetics</subject><subject>Lymphoma, Large B-Cell, Diffuse - pathology</subject><subject>Medical sciences</subject><subject>Nuclease Protection Assays</subject><subject>Oligonucleotide Array Sequence Analysis</subject><subject>Paraffin Embedding</subject><subject>Pharmacology. Drug treatments</subject><subject>Prognosis</subject><issn>1078-0432</issn><issn>1557-3265</issn><issn>1557-3265</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFUstu1DAUjRCIlsIngLxBbEjxM042SEPoFKQRVNCurRs_WqMkHuykYn6Nr8OhMwVWrHxtn3Pu6xTFc4JPCRH1G4JlXWLO6GnbfikJLqmQ7EFxTISQJaOVeJjjA-aoeJLSN4wJJ5g_Lo4oYRXHTBwXP1dazxEmi9oeUvLOa5h8GFFw6L13bk4WbSBeW_SubG3fo81u2N6EAZAfp4DObRz8CD1q7TjZiGA0aKUnf5sVzYHyde6m3dYmdJX8eI0AfZp1byErX8QwWf073yol2KEcrEMcoPdjufY_rHmNLiCCc_l-NnTWmCx76VOabXpaPHLQJ_tsf54UV-uzy_ZDufl8_rFdbUrNJZ1KU1tnOiM5sKrWTgrKsakdaSpsGPCmqYmuZOcqKwk1XS2NaDjQjpKm4Q0X7KR4e6e7nbvBGp07jdCrbfQDxJ0K4NW_P6O_UdfhVrFl_lWTBV7tBWL4nguf1OCTzpOB0YY5qQbLvLWa0f8ia1nXFFNWZaS4Q-oYUorW3ddDsFoMopbkalm-ygZZXheDZN6Lv5u5Zx0ckQEv9wBIGnoXYdQ-_cFxSqjAkv0CqKPGhw</recordid><startdate>20110601</startdate><enddate>20110601</enddate><creator>RIMSZA, Lisa M</creator><creator>WRIGHT, George</creator><creator>TUBBS, Raymond R</creator><creator>BRAZIEL, Rita M</creator><creator>DELABIE, Jan</creator><creator>MILLER, Tom P</creator><creator>STAUDT, Louis M</creator><creator>SCHWARTZ, Mark</creator><creator>CHAN, Wing C</creator><creator>JAFFE, Elaine S</creator><creator>GASCOYNE, Randy D</creator><creator>CAMPO, Elias</creator><creator>ROSENWALD, Andreas</creator><creator>OTT, German</creator><creator>COOK, James R</creator><general>American Association for Cancer Research</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7T5</scope><scope>7TM</scope><scope>H94</scope><scope>5PM</scope></search><sort><creationdate>20110601</creationdate><title>Accurate Classification of Diffuse Large B-Cell Lymphoma into Germinal Center and Activated B-Cell Subtypes Using a Nuclease Protection Assay on Formalin-Fixed, Paraffin-Embedded Tissues</title><author>RIMSZA, Lisa M ; WRIGHT, George ; TUBBS, Raymond R ; BRAZIEL, Rita M ; DELABIE, Jan ; MILLER, Tom P ; STAUDT, Louis M ; SCHWARTZ, Mark ; CHAN, Wing C ; JAFFE, Elaine S ; GASCOYNE, Randy D ; CAMPO, Elias ; ROSENWALD, Andreas ; OTT, German ; COOK, James R</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c472t-d8efdbd74a368cf75240d8f1960d3a49981c67bf6e712db87d594a2b219949453</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Antineoplastic agents</topic><topic>B-Lymphocyte Subsets - pathology</topic><topic>Biological and medical sciences</topic><topic>Gene Expression Profiling</topic><topic>Gene Expression Regulation, Neoplastic</topic><topic>Germinal Center - pathology</topic><topic>Hematologic and hematopoietic diseases</topic><topic>Humans</topic><topic>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</topic><topic>Lymphocyte Activation - genetics</topic><topic>Lymphoma, Large B-Cell, Diffuse - genetics</topic><topic>Lymphoma, Large B-Cell, Diffuse - pathology</topic><topic>Medical sciences</topic><topic>Nuclease Protection Assays</topic><topic>Oligonucleotide Array Sequence Analysis</topic><topic>Paraffin Embedding</topic><topic>Pharmacology. Drug treatments</topic><topic>Prognosis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>RIMSZA, Lisa M</creatorcontrib><creatorcontrib>WRIGHT, George</creatorcontrib><creatorcontrib>TUBBS, Raymond R</creatorcontrib><creatorcontrib>BRAZIEL, Rita M</creatorcontrib><creatorcontrib>DELABIE, Jan</creatorcontrib><creatorcontrib>MILLER, Tom P</creatorcontrib><creatorcontrib>STAUDT, Louis M</creatorcontrib><creatorcontrib>SCHWARTZ, Mark</creatorcontrib><creatorcontrib>CHAN, Wing C</creatorcontrib><creatorcontrib>JAFFE, Elaine S</creatorcontrib><creatorcontrib>GASCOYNE, Randy D</creatorcontrib><creatorcontrib>CAMPO, Elias</creatorcontrib><creatorcontrib>ROSENWALD, Andreas</creatorcontrib><creatorcontrib>OTT, German</creatorcontrib><creatorcontrib>COOK, James R</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Immunology Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Clinical cancer research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>RIMSZA, Lisa M</au><au>WRIGHT, George</au><au>TUBBS, Raymond R</au><au>BRAZIEL, Rita M</au><au>DELABIE, Jan</au><au>MILLER, Tom P</au><au>STAUDT, Louis M</au><au>SCHWARTZ, Mark</au><au>CHAN, Wing C</au><au>JAFFE, Elaine S</au><au>GASCOYNE, Randy D</au><au>CAMPO, Elias</au><au>ROSENWALD, Andreas</au><au>OTT, German</au><au>COOK, James R</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Accurate Classification of Diffuse Large B-Cell Lymphoma into Germinal Center and Activated B-Cell Subtypes Using a Nuclease Protection Assay on Formalin-Fixed, Paraffin-Embedded Tissues</atitle><jtitle>Clinical cancer research</jtitle><addtitle>Clin Cancer Res</addtitle><date>2011-06-01</date><risdate>2011</risdate><volume>17</volume><issue>11</issue><spage>3727</spage><epage>3732</epage><pages>3727-3732</pages><issn>1078-0432</issn><issn>1557-3265</issn><eissn>1557-3265</eissn><coden>CCREF4</coden><abstract>Classification of diffuse large B-cell lymphoma (DLBCL) into cell-of-origin (COO) subtypes based on gene expression profiles has well-established prognostic value. These subtypes, termed germinal center B cell (GCB) and activated B cell (ABC) also have different genetic alterations and overexpression of different pathways that may serve as therapeutic targets. Thus, accurate classification is essential for analysis of clinical trial results and planning new trials by using targeted agents. The current standard for COO classification uses gene expression profiling (GEP) of snap frozen tissues, and a Bayesian predictor algorithm. However, this is generally not feasible. In this study, we investigated whether the qNPA technique could be used for accurate classification of COO by using formalin-fixed, paraffin-embedded (FFPE) tissues. We analyzed expression levels of 14 genes in 121 cases of R-CHOP-treated DLBCL that had previously undergone GEP by using the Affymetrix U133 Plus 2.0 microarray and had matching FFPE blocks. Results were evaluated by using the previously published algorithm with a leave-one-out cross-validation approach. These results were compared with COO classification based on frozen tissue GEP profiles. For each case, a probability statistic was generated indicating the likelihood that the classification by using qNPA was accurate. When data were dichotomized into GCB or non-GCB, overall accuracy was 92%. The qNPA technique accurately categorized DLBCL into GCB and ABC subtypes, as defined by GEP. This approach is quantifiable, applicable to FFPE tissues with no technical failures, and has potential for significant impact on DLBCL research and clinical trial development.</abstract><cop>Philadelphia, PA</cop><pub>American Association for Cancer Research</pub><pmid>21364035</pmid><doi>10.1158/1078-0432.CCR-10-2573</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1078-0432
ispartof Clinical cancer research, 2011-06, Vol.17 (11), p.3727-3732
issn 1078-0432
1557-3265
1557-3265
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3107869
source AACR Journals; MEDLINE; Alma/SFX Local Collection; EZB Electronic Journals Library
subjects Antineoplastic agents
B-Lymphocyte Subsets - pathology
Biological and medical sciences
Gene Expression Profiling
Gene Expression Regulation, Neoplastic
Germinal Center - pathology
Hematologic and hematopoietic diseases
Humans
Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis
Lymphocyte Activation - genetics
Lymphoma, Large B-Cell, Diffuse - genetics
Lymphoma, Large B-Cell, Diffuse - pathology
Medical sciences
Nuclease Protection Assays
Oligonucleotide Array Sequence Analysis
Paraffin Embedding
Pharmacology. Drug treatments
Prognosis
title Accurate Classification of Diffuse Large B-Cell Lymphoma into Germinal Center and Activated B-Cell Subtypes Using a Nuclease Protection Assay on Formalin-Fixed, Paraffin-Embedded Tissues
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-20T21%3A19%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Accurate%20Classification%20of%20Diffuse%20Large%20B-Cell%20Lymphoma%20into%20Germinal%20Center%20and%20Activated%20B-Cell%20Subtypes%20Using%20a%20Nuclease%20Protection%20Assay%20on%20Formalin-Fixed,%20Paraffin-Embedded%20Tissues&rft.jtitle=Clinical%20cancer%20research&rft.au=RIMSZA,%20Lisa%20M&rft.date=2011-06-01&rft.volume=17&rft.issue=11&rft.spage=3727&rft.epage=3732&rft.pages=3727-3732&rft.issn=1078-0432&rft.eissn=1557-3265&rft.coden=CCREF4&rft_id=info:doi/10.1158/1078-0432.CCR-10-2573&rft_dat=%3Cproquest_pubme%3E907155832%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=878820236&rft_id=info:pmid/21364035&rfr_iscdi=true